Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elotuzumab and Nivolumab +/- Pomalidomide in Relapsed Refractory Multiple Myeloma
NCT03227432Phase 2Withdrawn
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2018
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in multiple myeloma (MM), sponsored by Dana-Farber Cancer Institute. Planned start Dec 2018; status: withdrawn.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03227432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03227432.